Elite Health Systems Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Elite Health Systems Inc (USNU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Elite Health Systems Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 125,938M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+50.3% annualized vs trailing 12 months), vs accelerating (+3.2%) for its tracked peer group.
- Profitability: Its -117.0% net margin compares with 12.4% for the peer group.
- Peer revenue share: Elite Health Systems Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.04M compares with $0.44M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
USNU Sales vs. its Competitors, Q2 2026
With a net margin of -116.95 %, Elite Health Systems Inc reported lower profitability than its competitors (12.41 %).
Elite Health Systems Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Elite Health Systems Inc vs. its Competitors, Q2 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Elite Health Systems Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Elite Health Systems Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Elite Health Systems Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Elite Health Systems Inc's competitor groups requires a Commercial License.
Elite Health Systems Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Elite Health Systems Inc | - | - | - | Yes |
| Competitors combined (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
USNU Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Zimmer Biomet Holdings Inc | 282.9% | Outperformed |
| 2 | Integra Lifesciences Holdings Corp | 282.9% | Outperformed |
| 3 | Medtronic Plc | 282.9% | Outperformed |
| 4 | Neurocrine Biosciences Inc | 282.9% | Outperformed |
| 5 | Stryker Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Elite Health Systems Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Elite Health Systems Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Elite Health Systems Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Elite Health Systems Inc |
28.52 | 3.49 |
 Abbott Laboratories |
191,969.10 | 48,229.00 |
 Medtronic Plc |
130,553.31 | 37,542.00 |
 Stryker Corp |
124,754.36 | 26,300.00 |
 Zimmer Biomet Holdings Inc |
20,691.30 | 8,508.80 |
 Neurocrine Biosciences Inc |
17,793.53 | 3,701.70 |
| SUBTOTAL | 486,931.84 | 125,941.77 |
Sign in to see all competitors of Elite Health Systems Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Elite Health Systems Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Elite Health Systems Inc's Competitors Named by the Company
Competitive relationships identified from Elite Health Systems Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Zimmer Biomet Holdings Inc | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Stryker Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Elite Health Systems Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Elite Health Systems Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Zimmer Biomet Holdings Inc | Americas Segment 63.91 % |
| Neurocrine Biosciences Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Elite Health Systems Inc .
Elite Health Systems Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Elite Health Systems Inc | 29 | 40,080 | -112,241 |
| Abbott Laboratories | 191,969 | 419,383 | 40,878 |
| Medtronic Plc | 130,553 | 395,179 | 55,463 |
| Stryker Corp | 124,754 | 469,643 | 64,696 |
| Zimmer Biomet Holdings Inc | 20,691 | 500,518 | 47,476 |
| Neurocrine Biosciences Inc | 17,794 | 1,850,850 | 351,250 |
| PEERS TOTAL | 486,903 | 435,130 | 52,226 |
Sign in to see all peers for Elite Health Systems Inc .
Elite Health Systems Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Zimmer Biomet Holdings Inc | US 58.44 % |
| Integra Lifesciences Holdings Corp | United States 72.80 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Elite Health Systems Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 48 companies in Elite Health Systems Inc's industry classification, broader than the peer set above. Market cap in millions of $.Elite Health Systems Inc ranks #0 of 48 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,787, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 112,399 | 39.38 % |
| 2 | Tenet Healthcare Corp | 24,372 | 8.54 % |
| 3 | Brightspring Health Services Inc | 15,968 | 5.59 % |
| 4 | Encompass Health Corporation | 14,251 | 4.99 % |
| 5 | Fresenius Medical Care Ag | 1,234 | 5.2% |
| 6 | Davita Inc | 1,234 | 5.2% |
| 7 | Universal Health Services Inc | 1,234 | 5.2% |
| 8 | Ensign Group Inc | 1,234 | 5.2% |
| 9 | Pacs Group Inc | 1,234 | 5.2% |
| 10 | Chemed Corporation | 1,234 | 5.2% |
| 0 | Elite Health Systems Inc | 34 | 0.00 % |
Market cap and industry share for the rest of Elite Health Systems Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-06-09.
Elite Health Systems Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 0.29 % | -10.34 % | 3.36 % | - | - | - | - | - |
| Operating Margin | 3.83 % | 48.53 % | 50.90 % | - | - | - | - | - |
| Return on Invested Capital | 1.51 % | 21.39 % | 22.86 % | -1.21 % | -42.13 % | -41.05 % | -34.86 % | -41.73 % |
| P/E | - | 28.1x | 4.1x | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Elite Health Systems Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,787 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Elite Health Systems Inc's dedicated Suppliers and Customers pages, not here.
Elite Health Systems Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+50.3% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 272.8 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Industry dominated by Hca Healthcare Inc , holding 39.38 % of industry market cap.
Methodology: see Methodology: SWOT Analysis.
Elite Health Systems Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Elite Health Systems Inc | 2.70 | 3.22 | - |
| Abbott Laboratories | 0.36 | 1.45 | 0.53 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Zimmer Biomet Holdings Inc | 0.25 | 1.93 | 0.60 |
| Neurocrine Biosciences Inc | 0.57 | 2.51 | - |
Sign in to see all peers for Elite Health Systems Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Elite Health Systems Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Elite Health Systems Inc | Q2 2026 | - | - |
| Abbott Laboratories | Q3 2026 | +14.5 % | -44.0 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +4.8 % | +30.1 % |
| Neurocrine Biosciences Inc | Q3 2026 | +41.2 % | -1.4 % |
| PEERS TOTAL | +12.7 % | -8.6 % |
Sign in to see all peers for Elite Health Systems Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Elite Health Systems Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Elite Health Systems Inc | Q2 2026 | - | - |
| Abbott Laboratories | Q3 2026 | +10.9 % | +3.4 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Zimmer Biomet Holdings Inc | Q2 2026 | +7.3 % | +45.3 % |
| Neurocrine Biosciences Inc | Q3 2026 | +104.6 % | -12.1 % |
Sign in to see all peers for Elite Health Systems Inc .
Elite Health Systems Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Elite Health Systems Inc | - | - | - |
| Abbott Laboratories | 4.54% | 5.14% | 9.00% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Zimmer Biomet Holdings Inc | 3.51% | 3.97% | 6.36% |
| Neurocrine Biosciences Inc | 13.69% | 16.94% | 19.74% |
Sign in to see all peers for Elite Health Systems Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Elite Health Systems Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Elite Health Systems Inc | - | 8.18 |
| Abbott Laboratories | 40.91 | 3.98 |
| Medtronic Plc | 298.79 | 3.48 |
| Stryker Corp | 34.54 | 4.74 |
| Zimmer Biomet Holdings Inc | 26.05 | 2.43 |
| Neurocrine Biosciences Inc | 25.01 | 4.81 |
| PEERS AVERAGE | 32.23 | 3.87 |
Sign in to see all peers for Elite Health Systems Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.